Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) has engaged IBN to assist with its corporate communications strategy, according to a press release. The move is intended to generate greater awareness for the clinical-stage biopharmaceutical company and its wholly owned subsidiary, MindWave Innovations Inc., which is developing institutional digital asset infrastructure.
IBN will leverage its investor-focused distribution network, including more than 5,000 syndication outlets, newsletters, social media channels, InvestorWire and other outreach tools, to increase visibility for Apimeds. The full press release can be viewed at https://ibn.fm/PdvmC.
Apimeds Pharmaceuticals US, Inc. is a clinical-stage biopharmaceutical company focused on developing non-opioid, biologic-based therapies for pain management. More information is available at www.ApimedsUS.com.
MindWave Innovations Inc. is developing enterprise blockchain infrastructure and institutional technology platforms through its MindChain ecosystem. Four ecosystems operate under MindChain: InsurTech through BlockAssure, which is developing a Bermuda-framework platform applying Bitcoin reserves as regulatory capital to support life and property and casualty underwriting; ClimateTech through AQUAE and the ALCI index, measuring, verifying and tokenizing ecosystem services into institutional-grade assets; HealthTech through the Apitox development program; and RWA Tech through Nexus Global Partners, bringing institutional real estate on-chain within a compliance-first, insurance-enhanced framework.
The engagement of IBN is significant because it aims to increase investor awareness of Apimeds’ dual focus: its biopharmaceutical operations and its subsidiary’s digital asset infrastructure. MindWave’s MindChain ecosystem combines insured custody, transparent reporting and technology-driven portfolio management to support risk-aware yield on Bitcoin reserves and institutional participation in the digital asset economy. This could attract investors interested in both healthcare and blockchain technology.
MissionIR, the communications platform issuing the press release, specializes in assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN, which delivers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution via IBN to millions of social media followers, and a full array of tailored corporate communications solutions. For more information, visit www.MissionIR.com.
The latest news and updates relating to APUS are available in the company’s newsroom at https://ibn.fm/APUS. The collaboration underscores the growing intersection of traditional biopharmaceutical companies and emerging digital asset technologies, potentially positioning Apimeds to appeal to a broader investor base.
